Humana coverage resumed with a Buy at Citi. Citi analyst Ralph Giacobbe resumed coverage of Humana with a Buy rating and $340 price target. The analyst continues to see the company as well positioned in an “attractive” Medicare Advantage end market that has “broad demographic/structural tailwinds.” This creates a solid long-term growth profile for Humana and makes the company a “coveted asset and providing valuation support in the least,” Giacobbe tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.